

**Table SII. The association between skin diseases and high sensitive C-reactive protein (hs-CRP) elevation**

Skin diseases <sup>a</sup>	hs-CRP levels			p-value	Skin diseases	hs-CRP levels			p-value
	< 1 mg/l n (%)	1–3 mg/l n (%)	> 3 mg/l n (%)			< 1 mg/l n (%)	1–3 mg/l n (%)	> 3 mg/l n (%)	
Eczemas					Skin infections				
No	864 (62.4)	384 (27.7)	137 (9.9)	0.354	No	675 (62.9)	296 (27.6)	102 (9.5)	0.239
Yes	310 (59.5)	149 (28.6)	62 (11.9)		Yes	499 (59.9)	237 (28.5)	97 (11.6)	
Atopic eczema					Fungal skin infections				
No	1,122 (61.9)	510 (28.1)	182 (10.0)	0.031	No	812 (63.1)	351 (27.3)	124 (9.6)	0.101
Yes	51 (56.0)	23 (25.3)	17 (18.7)		Yes	362 (58.5)	182 (29.4)	75 (12.1)	
Hand eczema					Pityriasis versicolor				
No	1,060 (61.1)	493 (28.4)	183 (10.5)	0.326	No	1,153 (61.7)	521 (27.9)	194 (10.4)	0.702
Yes	113 (66.9)	40 (23.7)	16 (9.5)		Yes	21 (55.3)	12 (31.6)	5 (13.2)	
Seborrheic eczema					Onychomycosis				
No	1,095 (62.0)	490 (27.7)	182 (10.3)	0.437	No	1,067 (61.8)	490 (28.4)	169 (9.8)	0.013
Yes	78 (56.5)	43 (31.2)	17 (12.3)		Yes	107 (59.4)	43 (23.9)	30 (16.7)	
Eczema nummulare					Tinea pedis				
No	1,152 (61.7)	522 (27.9)	194 (10.4)	0.770	No	875 (62.7)	382 (27.4)	138 (9.9)	0.202
Yes	21 (56.8)	11 (29.7)	5 (13.5)		Yes	299 (58.5)	151 (29.5)	61 (11.9)	
Eczema infectiosum					Tinea corporis				
No	1,159 (61.7)	523 (27.9)	195 (10.4)	0.443	No	1,170 (61.6)	530 (27.9)	198 (10.4)	0.791
Yes	14 (50.0)	10 (35.7)	4 (14.3)		Yes	4 (50.0)	3 (37.5)	1 (12.5)	
Contact eczema					Bacterial skin infections				
No	1,158 (61.4)	530 (28.1)	198 (10.5)	0.293	No	1,113 (62.2)	495 (27.7)	181 (10.1)	0.060
Yes	15 (78.9)	3 (15.8)	1 (5.3)		Yes	61 (52.1)	38 (32.5)	18 (15.4)	
Eczema staticum					Folliculitis				
No	1,166 (61.7)	529 (28.0)	195 (10.3)	0.113	No	1,113 (62.2)	495 (27.7)	182 (10.2)	0.093
Yes	7 (46.7)	4 (26.7)	4 (26.7)		Yes	61 (52.6)	38 (32.8)	17 (14.7)	
Neurodermatitis					Virus skin infections				
No	1,153 (61.7)	521 (27.9)	196 (10.5)	0.691	No	1,037 (61.4)	472 (27.9)	180 (10.7)	0.683
Yes	20 (57.1)	12 (34.3)	3 (8.6)		Yes	137 (63.1)	61 (28.1)	19 (8.8)	
Psoriasis					Verruca plantaris				
No	1,146 (61.6)	520 (27.9)	195 (10.5)	0.868	No	1,062 (61.5)	483 (28.0)	183 (10.6)	0.797
Yes	24 (58.5)	13 (31.7)	4 (9.8)		Yes	112 (62.9)	50 (28.1)	16 (9.0)	
Autoimmune diseases					Verruca palmaris				
No	1,126 (61.6)	513 (28.1)	188 (10.3)	0.556	No	1,144 (61.7)	518 (27.9)	193 (10.4)	0.908
Yes	48 (60.8)	20 (25.3)	11 (13.9)		Yes	30 (58.8)	15 (29.4)	6 (11.8)	
Lichen ruber planus					Hair follicle disorders				
No	1,169 (61.8)	528 (27.9)	196 (10.4)	0.161	No	760 (60.4)	360 (28.6)	139 (11.0)	0.257
Yes	5 (38.5)	5 (38.5)	3 (23.1)		Yes	414 (64.0)	173 (26.7)	60 (9.3)	
Dermatitis herpetiformis					Alopecia areata				
No	1,170 (61.6)	532 (28.0)	198 (10.4)	0.770	No	1,169 (61.6)	532 (28.0)	198 (10.4)	0.712
Yes	4 (66.7)	1 (16.7)	1 (16.7)		Yes	5 (71.4)	1 (14.3)	1 (14.3)	
Vitiligo					Androgenetic alopecia				
No	1,154 (61.6)	524 (28.0)	196 (10.5)	0.980	No	775 (60.3)	367 (28.5)	144 (11.2)	0.152
Yes	20 (62.5)	9 (28.1)	3 (9.4)		Yes	399 (64.4)	166 (26.8)	55 (8.9)	
Urticaria					Hyperhidrosis				
No	1,166 (61.5)	531 (28.0)	199 (10.5)	0.400	No	1,152 (61.8)	520 (27.9)	192 (10.3)	0.313
Yes	8 (80.0)	2 (20.0)	0 (0.0)		Yes	22 (52.4)	13 (31.0)	7 (16.7)	
Sebaceous gland diseases					Requirement of treatment <sup>b</sup>				
No	890 (63.7)	378 (27.0)	130 (9.3)	0.003	No	477 (62.7)	223 (29.3)	61 (8.0)	0.016
Yes	284 (59.9)	155 (30.5)	69 (13.6)		Yes	695 (60.8)	310 (27.1)	138 (12.1)	
Acne vulgaris									
No	1,090 (62.1)	482 (27.5)	183 (10.4)	0.207					
Yes	83 (55.3)	51 (34.0)	16 (10.7)						
Rosacea									
No	1,019 (63.0)	445 (27.5)	153 (9.5)	0.001					
Yes	154 (53.7)	87 (30.3)	46 (16.0)						
Perioral dermatitis									
No	1,165 (61.7)	528 (28.0)	195 (10.3)	0.376					
Yes	7 (50.0)	4 (28.6)	3 (21.4)						
Acne scars									
No	1,068 (62.3)	470 (27.4)	177 (10.3)	0.246					
Yes	105 (56.1)	61 (32.6)	21 (11.2)						

<sup>a</sup>Includes all skin diseases that were seen in more than 5 (n = 5) of the participants. Benign skin findings (such as seborrheic keratosis, cherry angiomas) are excluded from the analyses. <sup>b</sup>Includes study cases who had any skin disease that was classified as severe enough needing further evaluation or treatment.